LH Labcorp

Q3 2025 10-Q
Filed: Oct 31, 2025Period ending Sep 30, 2025
Health Care
Services-Medical LaboratoriesSEC EDGAR

Labcorp (LH) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 31, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

  • Revenue $3.56B Q3 FY25, up 8.6% YoY from $3.28B; organic growth 6.2%, acquisitions 1.7%, currency 0.7%
  • Operating margin Q3 FY25: Dx 16.3% vs 15.2% YoY, BLS 16.5% vs 16.4% YoY; total operating income $396.6M up 56.1% YoY
+3 more insights

Risk Factors

  • No material changes in risk factors from 2024 10-K carried forward
  • Pandemic impact risk persists with potential lab test volume fluctuations
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$3.6B

+8.6% YoY +1.0% QoQ

Net Income

$261M

+54.2% YoY +9.8% QoQ

Gross Margin

28.8%

+121bp YoY -89bp QoQ

Operating Margin

11.1%

+339bp YoY -5bp QoQ

Net Margin

7.3%

+217bp YoY +58bp QoQ

ROE

3.0%

Total Assets

$18.3B

EPS (Diluted)

$3.12

+56.0% YoY +9.9% QoQ

Operating Cash Flow

$387M

+39.6% YoY -37.6% QoQ

Source: XBRL data from Labcorp Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Labcorp

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.